EX-2.1 2 a18-41531_1ex2d1.htm EX-2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG AMAG PHARMACEUTICALS, INC. MAGELLAN MERGER SUB, INC., PEROSPHERE PHARMACEUTICALS INC. AND BRYAN E. LAULICHT, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated...Agreement and Plan of Merger • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 JurisdictionThis Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 12, 2018 by and among AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”), Magellan Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Perosphere Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Bryan E. Laulicht (the “Company Equityholder Representative”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG ALKERMES, INC., THINKER MERGER SUB, INC., ALKERMES PLC, RODIN THERAPEUTICS, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated as of November 14, 2019Agreement and Plan of Merger • November 25th, 2019 • Alkermes Plc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 25th, 2019 Company Industry JurisdictionThis Agreement and Plan of Merger (this “Agreement”) is made and entered into as of November 14, 2019 by and among Alkermes, Inc., a Pennsylvania corporation (the “Buyer”), Thinker Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Rodin Therapeutics, Inc., a Delaware corporation (the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney-in-fact of the Company Equityholders (the “Company Equityholder Representative”), and, solely for purposes of being bound by Section 10.16, Alkermes plc, an Irish company (“Parent”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMAG PHARMACEUTICALS, INC. MAGELLAN MERGER SUB, INC., PEROSPHERE PHARMACEUTICALS INC. AND BRYAN E. LAULICHT, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated as of December 12, 2018Agreement and Plan of Merger • December 13th, 2018 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 13th, 2018 Company Industry JurisdictionThis Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 12, 2018 by and among AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”), Magellan Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Perosphere Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Bryan E. Laulicht (the “Company Equityholder Representative”).